Untitled Document
OHSU Where Healing, Teaching and Discovery Come Together
OHSU Search OHSU OHSU Site Map Contact
OHSU Division of Hematology and Medical Oncology
About the Division Care Centers Patient Resources Our Faculty Research and Education News and Events
Dedicated to the study and treatment of cancer and disorders of the blood.


Ian Schnadig, MD

undefined

Degrees:

  • B.A., Trinity College  
  • M.D., Rush Medical College

Residency: Internal Medicine, Oregon Health & Science University

Fellowship:  Hematology & Medical Oncology - Oregon Health & Science University

Current Research (Principle Investigator): 

  • Prognostic Significance of Patient-Physician Disagreement About Performance Status in Patients with Advanced Cancer – poster discussion at ASCO 2007; manuscript underway
  • Aggressiveness of Cancer Care at the End of Life in the Managed Care Setting – submitted for funding
  • Comparison of Rescue Treatments for Breakthrough Chemotherapy-Induced Nausea and Vomiting - A Randomized Phase II Study – submitted for funding
  • Fosaprepitant As Rescue Therapy for Breakthrough Chemotherapy-Induced Nausea and Vomiting, A Pilot Study – submitted for funding
  • Evaluation of C-reactive protein (CRP) and Other Serum Biomarkers as Predictor(s) of Performance Status, Chemotherapy Toxicity and Serious Adverse Events in Patients Receiving Docetaxel for Metastatic Androgen-Independent Prostate Cancer – statistical analysis underway

Co-Investigator, OHSU Prostate Cancer Program Trials:

  • A Randomized, Phase II Study of Two Dose Levels of ATN-224 in Patients with Biochemically Relapsed, Hormone-Naïve Prostate Cancer
  • Phase II Study of the Early Use Of Docetaxel In Patients With Biochemical Relapse After Primary Therapy for Prostate Cancer And An Incomplete Response To Androgen Deprivation Therapy
  • A Randomized Multicenter Phase II Trial of Patupilone® (EPO906) Plus Prednisone Versus Docetaxel (Taxotere) Plus Prednisone in Patients with Metastatic Hormone Refractory Prostate Cancer
  • A Phase I/II, Open-Label, Dose-Escalation Study of MDX-010 Administered Every 3 Weeks for 4 Doses in Patients with Metastatic Hormone-Refractory Prostate Cancer
  • A Phase I/II Study of RAD001 with Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer
  • A Phase I/II Safety and Pharmacokinetic Study of Sutent® (SU011248) in Combination with Docetaxel (Taxotere®) and Prednisone in Patients with Metastatic Hormone Refractory Prostate Cancer
  • A Phase I, Open-label, Dose-Escalation Safety and Pharmacokinetic Study of Medivation® (MDV3100) in Patients with Castration-Resistant Prostate Cancer
  • Phase I/II trial of Epothilone Analog BMS-247550 (Ixabepilone), Mitoxantrone, and Prednisone in Hormone Refractory Prostate Cancer Patients Previously Treated with Chemotherapy
  • A Phase II study of Paclitaxel Poliglumex (PPX) in Combination with Transdermal Estradiol for the Treatment of Androgen Independent Prostate Cancer After Docetaxel Chemotherapy
  • A Randomized Phase II study of Intermittent Chemotherapy or Intermittent Chemotherapy with Maintenance GM-CSF in Patients with Previously Untreated Metastatic Hormone Refractory Prostate Cancer 

Personal Interests:  Cycling, hiking, reading, music: jazz, blues, Grateful Dead